I-Mab scores second China IND with its CD38 antibody

Oct. 23, 2019

HONG KONG - China and U.S.-based I-Mab Biopharma Co Ltd. has won two IND clearances for TJ-202/MOR-202 from China's National Medical Products Administration (NMPA).

I-Mab scores second China IND with its CD38 antibody

Oct. 22, 2019

By David Ho

No Comments

HONG KONG - China and U.S.-based I-Mab Biopharma Co Ltd. has won two IND clearances for TJ-202/MOR-202 from China's National Medical Products Administration (NMPA).

Today's news in brief

BioWorld

BioWorld briefs for Nov. 25, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 25, 2024.

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection

BioWorld Asia

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual...